|
EPS15L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.3761999984041E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.60469999954671E-07 |
| Normal-vs-Stage2 |
1.424060E-02 |
| Normal-vs-Stage3 |
4.8517000417192E-09 |
| Normal-vs-Stage4 |
6.63489999608302E-08 |
| Stage1-vs-Stage2 |
7.029900E-02 |
| Stage1-vs-Stage3 |
6.782000E-02 |
| Stage1-vs-Stage4 |
2.426200E-01 |
| Stage2-vs-Stage3 |
5.917000E-03 |
| Stage2-vs-Stage4 |
1.816140E-02 |
| Stage3-vs-Stage4 |
8.174400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.34029998211105E-09 |
| Normal-vs-AfricanAmerican |
3.610200E-02 |
| Normal-vs-Asian |
8.01430000000325E-05 |
| Caucasian-vs-AfricanAmerican |
6.092000E-02 |
| Caucasian-vs-Asian |
3.489600E-01 |
| AfricanAmerican-vs-Asian |
3.162600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.5204399999913E-05 |
| Normal-vs-Female |
5.9189999568332E-09 |
| Male-vs-Female |
3.507000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65190000012139E-07 |
| Normal-vs-Age(41-60Yrs) |
1.40459999964371E-07 |
| Normal-vs-Age(61-80Yrs) |
5.8056999996392E-07 |
| Normal-vs-Age(81-100Yrs) |
1.798600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.746200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.705800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.034200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.333600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.554800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.784800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.648400E-04 |
| Classical-VS-Follicular |
1.349000E-01 |
| Classical-VS-Other |
5.395400E-01 |
| Classical-VS-Normal |
5.26250000243422E-08 |
| Tall-VS-Follicular |
8.3522000000058E-05 |
| Tall-VS-Other |
3.020400E-01 |
| Tall-VS-Normal |
3.39799965942689E-10 |
| Follicular-VS-Other |
3.233200E-01 |
| Follicular-VS-Normal |
1.084300E-03 |
| Other-VS-Normal |
4.719000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.52990000001907E-06 |
| Normal-vs-N1 |
4.76530037651912E-10 |
| N0-vs-N1 |
1.304440E-02 |
|
|
